MetaLabs reported a consolidated revenue of 8.4 billion won and an operating loss of 800 million won for the first quarter of this year on the 16th. The net loss for the period was approximately 70 million won, representing a reduction of over 95% compared to the same period last year.
A MetaLabs official noted, "Despite the global economic downturn, we maintained revenue levels comparable to the same period last year," adding, "The significant reduction in net loss was due to management efficiency efforts such as rent savings from the transfer of headquarters and improvements in the commission structure."
MetaLabs plans to strengthen the core businesses of its subsidiaries starting in the second quarter of this year and aims to enhance its capabilities in specialized medical consulting for hair loss to promote growth.
Its subsidiary, Meta S&C, will strengthen sales of its independently developed hospital customer management (CRM) solution. It will also continue to promote a "total hair loss healthcare" business that incorporates platform development and big data research.
Another subsidiary, MomoLabs, will expand its cooperation with hospitals nationwide. There are plans to further enhance the healthcare value chain through its subsidiary, METACARE, which distributes pharmaceuticals and medical devices.
A MetaLabs official said, "We are growing into a total healthcare corporation equipped with the highest level of medical consulting capabilities for hair loss in the country, along with IT solutions, medical infrastructure, and the ability to supply pharmaceuticals and medical devices," and added, "We will strive for quarterly net profit turnaround through continuous revenue expansion in the healthcare sector and thorough expense management."
Meanwhile, MetaLabs' listed subsidiary, METACARE, recorded revenue of 6 billion won and an operating profit of 530 million won for the first quarter of this year. These figures represent increases of 23% and 47%, respectively, compared to the same period last year.